الفهرس 
Historical BriefOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition predominantly affecting women, characterized by urinary symptoms and pelvic pain. Diagnosis entails exclusion and the presence of symptoms for 6 weeks to 6 months. Various treatments, including intravesical therapies like platelet-rich plasma (PRP) injections, aim to improve bladder function and quality of life by addressing symptom severity and recurrence.
Aim of the Work: To assess the effectiveness of submucosal intravesical injection of autologous platelet-rich plasma in the treatment of IC/PBS resistant to conventional methods of treatment.
Patients and Methods: This is a one-arm clinical trial conducted at Ain Shams University hospitals in Cairo, Egypt, from April 1, 2021, to April 1, 2023, involving 30 Egyptian patients aged 30-50 with interstitial cystitis/bladder pain syndrome (IC/BPS). Patients undergo preoperative assessments, receive 20 submucosal injections of platelet-rich plasma (PRP) solution, and are followed up postoperatively. The treatment outcome is evaluated using the Global Response Assessment (GRA) scale at 6 months.
Results: The study demonstrates significant improvements in multiple parameters post-treatment with platelet-rich plasma (PRP) for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS). Reductions were observed in ICSI, ICPI, OSS, VAS for pain, frequency, nocturia, and FBC after 1, 3, and 6 months compared to baseline, all with p-values < 0.001. Additionally, postoperative complications, notably hematuria and UTI, significantly decreased. The GRA at 6 months showed a 63.3% success rate. Significant differences between improvement and failure groups were noted in multiple parameters, supporting PRP’s efficacy in managing IC/PBS resistant to conventional therapies.
Conclusion: The study demonstrates that submucosal intravesical injection of autologous platelet-rich plasma (PRP) offers a promising treatment option for IC/PBS patients resistant to conventional therapies, with a 63.3% success rate and significant symptom improvement, suggesting PRP’s potential in urothelial regeneration. Further research is warranted.